{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:24:39Z","timestamp":1792794279333,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["P.I. Poulikakos is supported by the NIH\/NCI (R01CA204314, R01CA240362, and R01CA238229)"],"award-info":[{"award-number":["P.I. Poulikakos is supported by the NIH\/NCI (R01CA204314, R01CA240362, and R01CA238229)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["P.I. Poulikakos is supported by the NIH\/NCI (R01CA204314, R01CA240362, and R01CA238229)"],"award-info":[{"award-number":["P.I. Poulikakos is supported by the NIH\/NCI (R01CA204314, R01CA240362, and R01CA238229)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"name":"NIH\/NCI","award":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"],"award-info":[{"award-number":["1R01CA244899-01A1 \u2013 Development of a multi-omic clinical decision platform to guide personalized therapy (PI-Dr. Samir Parekh)"]}]},{"DOI":"10.13039\/100010555","name":"Mount Sinai Health System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still relapse and there are currently no clear therapeutic options in post-CAR-T settings. In this report, we present a case of a post-BCMA CAR-T relapsed\/refractory (RR) MM patient with skin extramedullary disease (EMD) in which a novel MAPK inhibition combinatorial strategy was implemented based on next-generation sequencing and in vitro experiments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 61-year-old male with penta-refractory MM penta- (IgA lambda), ISS stage 3 with hyperdiploidy, gain of 1q21 and del13 was treated with anti-BCMA CAR-T cell therapy, achieving a best response of VGPR. He progressed after 6\u00a0months and was salvaged for a short period with autologous stem cell transplantation. Eventually, he progressed with extramedullary disease manifested as subcutaneous nodules. Based on whole-exome sequencing, we identified a BRAF (V600E) dominant subclone in both bone marrow and cutaneous plasmacytoma. Following in vitro experiments, and according to our previous studies, we implemented a triple MAPK inhibition strategy under which the patient achieved a very good partial response for 110\u00a0days, which allowed to bridge him to subsequent clinical trials and eventually achieve a stringent complete response (sCR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Here, we show the applicability, effectiveness, and tolerability the triple MAPK inhibition strategy in the context of post-BCMA CAR-T failure in specific subset of patients. The triple therapy could bridge our hospice bound RRMM patient with BRAF (V600E) to further therapeutic options where sCR was achieved. We will further evaluate triple MAPK inhibition in patients with BRAF V600E in a precision medicine clinical trial launching soon.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-022-01330-3","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T09:03:04Z","timestamp":1660726984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation"],"prefix":"10.1186","volume":"15","author":[{"given":"Muhammad","family":"Elnaggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Agte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Melnekoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Adamopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Kappes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Leshchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Verina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulikos I.","family":"Poulikakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"5","key":"1330_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.36","volume":"6","author":"J Xu","year":"2017","unstructured":"Xu J, et al. Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation. Oncogenesis. 2017;6(5): e337.","journal-title":"Oncogenesis"},{"issue":"9","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","volume":"6","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer. 2020;6(9):797\u2013810.","journal-title":"Trends Cancer"},{"issue":"5","key":"1330_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","volume":"22","author":"P Lito","year":"2012","unstructured":"Lito P, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22(5):668\u201382.","journal-title":"Cancer Cell"},{"issue":"3","key":"1330_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran RB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227\u201335.","journal-title":"Cancer Discov"},{"issue":"7","key":"1330_CR5","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","volume":"11","author":"C Adamopoulos","year":"2021","unstructured":"Adamopoulos C, et al. Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling. Cancer Discov. 2021;11(7):1716\u201335.","journal-title":"Cancer Discov"},{"issue":"1","key":"1330_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109788","volume":"37","author":"MA Stockslager","year":"2021","unstructured":"Stockslager MA, et al. Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Rep. 2021;37(1): 109788.","journal-title":"Cell Rep"},{"issue":"4","key":"1330_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/2159-8290.CD-12-0018","volume":"2","author":"S Chandarlapaty","year":"2012","unstructured":"Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2012;2(4):311\u20139.","journal-title":"Cancer Discov"},{"issue":"12","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928\u201342.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1330_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;17(11):676\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1330_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI, et al. Cardiovascular Adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8): e198890.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1330_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","volume":"17","author":"M Banks","year":"2017","unstructured":"Banks M, et al. Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol. 2017;17(4):487\u201393.","journal-title":"Cardiovasc Toxicol"},{"issue":"3","key":"1330_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00277-018-3547-7","volume":"98","author":"S Okabe","year":"2019","unstructured":"Okabe S, et al. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation. Ann Hematol. 2019;98(3):723\u201333.","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"1330_CR13","first-page":"3084","volume":"130","author":"SM Larson","year":"2017","unstructured":"Larson SM, et al. Inhibition of PI3K Alpha and PI3K delta with copanlisib shows preclinical activity as a single agent and in combination in multiple myeloma. Blood. 2017;130(Supplement 1):3084\u20133084.","journal-title":"Blood"},{"issue":"17","key":"1330_CR14","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, et al. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884\u201390.","journal-title":"Bioinformatics"},{"issue":"14","key":"1330_CR15","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"issue":"9","key":"1330_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"16","key":"1330_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16): e131.","journal-title":"Nucleic Acids Res"},{"key":"1330_CR18","doi-asserted-by":"crossref","unstructured":"Khanna, A., et al., Bam-readcount -- rapid generation of basepair-resolution sequence metrics. ArXiv, 2021.","DOI":"10.21105\/joss.03722"},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s42003-018-0023-9","volume":"1","author":"G Narzisi","year":"2018","unstructured":"Narzisi G, et al. Genome-wide somatic variant calling using localized colored de Bruijn graphs. Commun Biol. 2018;1:20.","journal-title":"Commun Biol"},{"issue":"8","key":"1330_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim S, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15(8):591\u20134.","journal-title":"Nat Methods"},{"issue":"1","key":"1330_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s12859-020-03919-2","volume":"21","author":"S Gillis","year":"2020","unstructured":"Gillis S, Roth A. PyClone-VI: scalable inference of clonal population structures using whole genome data. BMC Bioinform. 2020;21(1):571.","journal-title":"BMC Bioinform"},{"issue":"9","key":"1330_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41592-018-0108-x","volume":"15","author":"G Caravagna","year":"2018","unstructured":"Caravagna G, et al. Detecting repeated cancer evolution from multi-region tumor sequencing data. Nat Methods. 2018;15(9):707\u201314.","journal-title":"Nat Methods"},{"issue":"1","key":"1330_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"7","key":"1330_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"6","key":"1330_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882\u20133.","journal-title":"Bioinformatics"},{"key":"1330_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"issue":"11","key":"1330_CR27","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1080\/10428194.2017.1421760","volume":"59","author":"V Ramakrishnan","year":"2018","unstructured":"Ramakrishnan V, Kumar S. PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leuk Lymphoma. 2018;59(11):2524\u201334.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1330_CR28","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1073\/pnas.0900780106","volume":"106","author":"CA Pratilas","year":"2009","unstructured":"Pratilas CA, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009;106(11):4519\u201324.","journal-title":"Proc Natl Acad Sci U S A"}],"updated-by":[{"DOI":"10.1186\/s13045-023-01449-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000}}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01330-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T17:09:44Z","timestamp":1683565784000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01330-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01330-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13045-023-01449-x","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13045-023-01449-x","URL":"https:\/\/doi.org\/10.1186\/s13045-023-01449-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the samples have been collected from the patient under study ID # 18-00456 approved by the institutional review board (IRB) of Icahn school of Medicine at Mount Sinai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient was physician-referred as part of the MM banking protocol approved by the Mount Sinai Institutional Review Board. Written informed consent was obtained before samples collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.I. Poulikakos reports research grants to the Institution by Black Diamond Therapeutics and Verastem Oncology. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals.\u00a0Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}